Alexion Pharmaceuticals

ULTOMIRIS

View Prices
  1. Home
    2.  / 
  2. J Code
    3.  / ULTOMIRIS – J1303

Manufacturer:

Alexion Pharmaceuticals

Name:

ULTOMIRIS

HCPCS Code Descriptor:

Injection, ravulizumab-cwvz, 10 mg

Category:

J Code

HCPCS:

J1303

NDC(s):

25682-0025-01, 25682-0028-01

Primary Type:

Immunology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

ULTOMIRIS is an Immunology drug manufactured by Alexion Pharmaceuticals and administered via the Intravenous route of administration. The J Code: J1303 is aligned to the drug ULTOMIRIS.

Ultomiris is belongs to a class of drugs known as monoclonal antibodies. This drug works by inhibiting the C5 protein in the terminal complement cascade of the patient’s immune system. Ultomiris is a branded drug manufactured by Alexion Pharmaceuticals. Prior to its J Code assignment (J1303) in October 2019, Ultomiris was aligned to the C Code: C9052. Patient assistance programs can for Ultomiris can be found through Alexion’s OneSource.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

10/1/19

HCPCS Effective Date:

10/1/19

HCPCS Short Description:

Inj., ravulizumab-cwvz 10 mg

Billing and Coding Guide:

Not Found

Patient Assistance:

https://alexiononesource.com/